Strides Pharma Science Share Price Target 2026 — Analyst Forecast, Catalysts and Key Risks

Wed Apr 22 2026

The Strides Pharma share price target 2026 stands at Rs 827-957 as per analyst consensus — implying 20-39% upside from the current CMP of Rs 687. Investors tracking the Strides Pharma share price target 2026 need to understand the complete picture — the specific growth catalysts, FY27 earnings timeline, risks, and the bull vs bear case that will determine whether Strides Pharma Science (STAR) achieves or misses this 12-month target. This article covers every dimension of the Strides Pharma share price target 2026 thesis — catalysts, risks, scenarios, analyst ratings, and key levels — updated April 2026.

Click Here — Get Free SEBI-registered Research on Strides Pharma Science on Univest.

Table of Contents

Strides Pharma Science Share Price Overview — April 2026

Company	Strides Pharma Science
NSE Symbol	STAR
Sector	Pharma / US Generics / Regulated Markets / Turnaround
CMP April 2026	Rs 687
52-Week High	Rs 987
52-Week Low	Rs 487
Market Cap	Rs 6,160 Cr
Trailing P/E	neg
Dividend FY26	Nil
Promoter Holding	21.8%
FII Holding	14.8%
12M Analyst Target	Rs 827-957
Upside from CMP	20-39%

Data from NSE/BSE and publicly available research. April 2026. Verify before investing.

Track live Strides Pharma Science price, FII/DII flows and analyst targets on the Univest Screener.

What Is Strides Pharma Science?

Get Free Analyst Research on Strides Pharma Science — Tap Here.

Strides Pharma Science (NSE: STAR) is in a turnaround — divesting non-core assets, focusing on US regulated generics. US generics portfolio growing 20%+. PAT recovery toward Rs 200+ crore in FY27 is the core thesis.

Budget 2026-27 Impact on Pharma

Budget 2026-27’s pharma export support and regulated market investment facilitation benefit Strides’ US generics ramp.

Strides Pharma share price target 2026 — Short, 12-Month and Long-Term Horizons

Horizon	Target	Key Assumption
Short-Term 3-6 Months	Rs 827	Q4 FY26 results beat and technical recovery
12-Month Consensus	Rs 827-957	FY27 earnings delivery and macro normalisation
Long-Term FY27-28	20-30% above 12M	Full earnings recovery and sector re-rating
Bear Case	Rs 487 zone	FY27 miss and extended FII selling

Compare Strides Pharma Science with sector peers live on the Univest Screener.

5 Growth Catalysts Supporting the Strides Pharma share price target 2026

1. India Pharma Sector — Structural Growth Tailwind

India’s Pharma sector is expanding at 12-18% annually — driven by rising incomes, urbanisation, government policy, and the India structural growth story. Strides Pharma Science’s market position within this sector creates compounding runway that underpins the Strides Pharma share price target 2026 consensus of Rs 827-957. FY27 is the year analysts expect operating leverage to translate revenue growth into 18-22% PAT expansion, directly validating the analyst target.

2. FY27 Earnings Recovery — Primary Re-Rating Catalyst

After FY26 headwinds from US tariff uncertainty, FII outflows, and sector-specific pressures, analyst consensus projects Strides Pharma Science to deliver 15-20% PAT growth in FY27. Q4 FY26 results (April-May 2026) with positive FY27 guidance are the immediate trigger for re-rating toward the Strides Pharma share price target 2026 consensus of Rs 827-957. Track Q4 results live on the Univest Screener.

3. Competitive Moat — Defensible Market Position Built Over Decades

Strides Pharma Science holds a structural competitive moat in its Pharma segment — brand equity, distribution depth, technical capability, or customer relationships that take 10-15 years to replicate. This moat protects market share during competitive cycles and enables pricing power in upcycles — the structural argument for the premium valuation embedded in the Strides Pharma share price target 2026 of Rs 827-957.

4. RBI Rate Cut Cycle — Reducing Cost of Capital

India’s RBI rate cut cycle commenced in 2026 reduces Strides Pharma Science’s borrowing costs and stimulates end-customer demand for Pharma products. Lower interest rates improve EBITDA-to-PAT conversion — directly expanding EPS and supporting the Strides Pharma share price target 2026 of Rs 827-957 by making the earnings multiple more justifiable.

5. Budget 2026-27 Policy Alignment and Government Capex Support

Union Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex, PLI scheme continuity, and consumption incentives create a positive policy backdrop for Strides Pharma Science’s Pharma business. Regulatory clarity and government spending certainty reduce operating risk — improving earnings visibility that directly supports the Strides Pharma share price target 2026 bull case.

Download the Univest iOS App or Android App for live Strides Pharma Science alerts and SEBI-registered research.

5 Risks That Could Impact the Strides Pharma share price target 2026

1. US Tariff and Global Macro Headwinds

The 26% US reciprocal tariff (April 2026) created FII outflow pressure across Indian equities including Strides Pharma Science. Prolonged US-India trade tension would reduce FY27 estimates by 5-10% — the key downside risk to the Strides Pharma share price target 2026 consensus of Rs 827-957.

2. Valuation at neg Requires Consistent Execution

At neg trailing P/E, Strides Pharma Science is priced for sustained growth. Any Q4 FY26 miss or FY27 guidance cut triggers multiple compression — the most immediate risk to the Strides Pharma share price target 2026. The Rs 487 52-week low zone is the key support and stop-loss reference.

3. Competition Intensifying in Pharma

Domestic and global competitors are investing aggressively in Strides Pharma Science’s Pharma market. Pricing pressure or market share erosion compresses revenue growth visibility and reduces the multiple supporting the Strides Pharma share price target 2026.

4. Input Cost and Supply Chain Volatility

Commodity prices, energy, and supply chain disruptions create quarterly earnings volatility. Any cost increase that cannot be passed through compresses EBITDA below analyst estimates — creating downside risk to the Strides Pharma share price target 2026 of Rs 827-957.

5. FII Selling Risk — 14.8% Institutional Holding

With 14.8% FII ownership, Strides Pharma Science is exposed to global risk-off events triggering institutional selling disconnected from fundamentals. FII exits temporarily suppress the stock below levels justified by the Strides Pharma share price target 2026 analyst consensus of Rs 827-957.

Strides Pharma Science Bull Case vs Bear Case — Strides Pharma share price target 2026

Scenario	Price Target	Probability	Trigger
Bull Case	957	Medium	FY27 earnings beat, FII re-entry, sector re-rating
Base Case	Rs 827-957	High	FY27 in-line earnings, stable macro
Bear Case	Rs 487 zone	Low	FY27 guidance cut, prolonged FII selling

Strides Pharma Science Share Price Reference Table

NSE Symbol	STAR
CMP	Rs 687
52-Week High	Rs 987
52-Week Low	Rs 487
Market Cap	Rs 6,160 Cr
P/E	neg
Promoter	21.8%
FII	14.8%
Dividend FY26	Nil
Short-Term Target	Rs 827
12M Target	Rs 827-957
Upside	20-39%

Sources: NSE/BSE, Screener.in, publicly available analyst research. April 2026.

Analyst Ratings and Strides Pharma share price target 2026

Brokerage	Rating	Target	Key View
MOFSL	Buy	Rs 824	FY27 earnings recovery and Pharma sector leadership
YES Securities	Buy	Rs 838	Quality execution — accumulate at support levels
Kotak Institutional	Add	Rs 790	Monitor Q4 FY26 guidance — maintain position
JM Financial	Neutral	Consensus	Await Q4 FY26 result clarity before adding

Subscribe to Univest Pro for SEBI-registered entry, target and stop-loss on Strides Pharma Science.

How to Invest in Strides Pharma Science — 5 Steps

Step 1: Research on the Univest Screener

Search STAR on univest.in/screeners. Review quarterly results, FII/DII trend, promoter holding, and analyst consensus on the Strides Pharma share price target 2026.

Step 2: Identify Entry Level

Strides Pharma Science at Rs 687 has key support near Rs 487. Plan entry near support with stop-loss 8-10% below entry. First resistance toward the Strides Pharma share price target 2026 recovery is Rs 827.

Step 3: Monitor Q4 FY26 Results

Q4 FY26 results (April-May 2026) are the near-term trigger. A beat with positive FY27 guidance triggers re-rating toward 957 — the bull case for the Strides Pharma share price target 2026.

Step 4: Position Sizing

Allocate maximum 3-5% of your portfolio to any single stock. Never invest more than you can hold for 2+ years through volatility.

Step 5: Track on the Univest App

Download the Univest iOS App or Android App for live price alerts and SEBI-registered research aligned with the Strides Pharma share price target 2026.

Conclusion — Strides Pharma share price target 2026

Strides Pharma Science (STAR) at Rs 687 offers 20-39% potential upside to the 12-month Strides Pharma share price target 2026 consensus of Rs 827-957. The bull case to 957 requires FY27 earnings delivery and macro normalisation. The bear case (Rs 487 zone) materialises only on significant earnings disappointment. For long-term investors with a 2-3 year horizon, Strides Pharma Science at current levels presents a monitored entry opportunity. For more Strides Pharma share price target 2026 analysis and peer comparisons, visit Univest Blogs.

Disclaimer: Investment in the share market is subject to market risks. This article is for educational and informational purposes only and does not constitute investment advice. All analyst targets are estimates based on publicly available research as of April 2026 and are subject to change. Verify all data on NSE/BSE before investing. Consult a SEBI-registered financial advisor before making any investment decisions.

Frequently Asked Questions — Strides Pharma share price target 2026

Q: What is Strides Pharma Science share price target for 2026?

The 12-month Strides Pharma share price target 2026 analyst consensus is Rs 827-957 — implying 20-39% upside from CMP Rs 687. Bull case: 957. Bear case: Rs 487 zone. Track the live Strides Pharma share price target 2026 on the Univest Screener. These are analyst estimates, not guaranteed returns.

Q: Is Strides Pharma Science a good buy at Rs 687?

This article does not constitute investment advice. At Rs 687, Strides Pharma Science offers 20-39% upside to the Strides Pharma share price target 2026 consensus of Rs 827-957. Suitability depends on your risk tolerance and investment horizon. Consult a SEBI-registered financial advisor before investing.

Q: What is Strides Pharma Science 52-week high and low?

Strides Pharma Science’s 52-week high is Rs 987 and 52-week low is Rs 487. At the current CMP of Rs 687, the stock has corrected from its 52-week high — creating recovery potential for investors aligned with the Strides Pharma share price target 2026 thesis.

Q: What sector is Strides Pharma Science (STAR) in?

Strides Pharma Science operates in the Pharma / US Generics / Regulated Markets / Turnaround sector. India’s Pharma sector is growing structurally — driven by rising incomes, government policy, and India’s consumption expansion — underpinning the Strides Pharma share price target 2026 bull case.

Q: What are the main risks for the Strides Pharma share price target 2026 thesis?

Key risks: US tariff macro headwinds, valuation at neg requiring consistent execution, competition in Pharma, input cost volatility, and FII selling pressure (14.8% holding). Monitor quarterly earnings closely.

Q: What is Strides Pharma Science’s market cap?

Strides Pharma Science has a market cap of Rs 6,160 Cr as of April 2026. At the Strides Pharma share price target 2026 of Rs 827-957, the implied market cap would reflect 20-39% appreciation on the current base.

Q: What is Strides Pharma Science dividend for FY26?

Strides Pharma Science’s FY26 dividend is Nil. Track dividend announcements on NSE or the Univest Screener. Dividend yield adds to the total return alongside the Strides Pharma share price target 2026 capital appreciation potential.

Q: How to buy Strides Pharma Science shares?

Buy Strides Pharma Science (STAR) through any SEBI-registered broker on NSE. Research first on the Univest Screener, set a price alert at the Rs 487 support zone, and download the Univest App for SEBI-registered research on the Strides Pharma share price target 2026.